Gal Wald, MD, on the rationale for trial of BCG plus gemcitabine in NMIBC
December 6th 2024"Combination therapies have now become the forefront of our field, and we are trying to do better to avoid BCG-unresponsive disease, as well as progression to either muscle-invasive or metastatic disease," says Gal Wald, MD.